Mizoribine: A New Approach in the Treatment of Renal Disease

Table 3

Comparison between laboratory findings in the three groups at the latest follow-up examination.

	PWD (𝑛=21)	PWD-pulse (𝑛=20)	PWDM (𝑛=20)
The duration from initiation of therapy (years)	8.9±5.2	8.1±3.9	7.7±3.8
Urinary protein excretion (mg/m^2/hr)	17±10^(a)	22±20^(b)	6±6^(a,b)
Patients with severe proteinuria (<50 mg/m^2/hr)	19±9^(c)	25±22^(d)	5±5^(c,d)
Patients with mild proteinuria (<50 mg/m^2/hr)	14±8^(e)	18±15^(f)	7±6^(e,f)
Hematuria (macro) (cases)	15 (5)^(g)	14 (6)^(h)	5 (0)^(g,h)
Serum albumin (g/L)	34±4	32±6	36±5
Serum creatinine (𝜇moI/L)	52±39^(e,i)	78±59^(e,i)	44±15^(i)

^{(a,c,d,e,f,g,h)}𝑃<.05.
^(b,i)𝑃<.01.